Publications by authors named "Conrad Lewanski"

Claim this Profile
L
Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy.
Sanjay Popat, Adam Januszewski, Mary O'Brien, Tanya Ahmad, Conrad Lewanski

Br J Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial heterogeneity of radiolabeled choline positron emission tomography in tumors of patients with non-small cell lung cancer: first-in-patient evaluation of [F]fluoromethyl-(1,2-H)-choline.
Suraiya Dubash, Marianna Inglese, Francesco Mauri, Kasia Kozlowski, Pritesh Trivedi, Conrad Lewanski

Theranostics· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life with second or third line -paclitaxel-based regimens in advanced non-small-cell lung cancer.
Santiago Ponce Aix, Denis Talbot, Ramaswamy Govindan, Manuel Cobo Dols, Pieter E Postmus, Conrad Lewanski

Future Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
David J Pinato, Sarah Howlett, Diego Ottaviani, Heather Urus, Aisha Patel, Conrad Lewanski

JAMA Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
Siow Ming Lee, Sunil Upadhyay, Conrad Lewanski, Stephen Falk, Geraldine Skailes

Eur J Cancer· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
Daniel Morgensztern, Manuel Cobo, Santiago Ponce Aix, Pieter E Postmus, Conrad R Lewanski

Cancer· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice.
Raffaele Califano, Rohit Lal, Conrad Lewanski, Marianne C Nicolson, Christian H Ottensmeier

Future Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
Luis G Paz-Ares, Maurice Pérol, Tudor-Eliade Ciuleanu, Ruben Dario Kowalyszyn, Martin Reck, Conrad R Lewanski

Lung Cancer· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial.
David Ferry, Lucinda Billingham, Hugh Jarrett, David Dunlop, Penella J Woll, Conrad Lewanski

Eur J Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).
Siow Ming Lee, Mary Falzon, Fiona Blackhall, James Spicer, Marianne Nicolson, Conrad Lewanski

J Clin Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.
Ian A Cree, Richard Booton, Paul Cane, John Gosney, Merdol Ibrahim, Conrad Lewanski

Histopathology· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial.
Amelia O Clive, Hazel Taylor, Lee Dobson, Paula Wilson, Emma de Winton, Conrad Lewanski

Lancet Oncol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Louis Fehrenbacher, Alexander Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Conrad Lewanski

Lancet· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.
Carlo Palmieri, Iain Rj Macpherson, Kelvin Yan, Felipe Ades, Pippa Riddle, Conrad Lewanski

Oncotarget· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Suresh Senan, Anthony Brade, Lu-Hua Wang, Johan Vansteenkiste, Shaker Dakhil, Conrad Lewanski

J Clin Oncol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Maurice Pérol, Tudor-Eliade Ciuleanu, Oscar Arrieta, Kumar Prabhash, Konstantinos N Syrigos, Conrad R Lewanski

Lung Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Edward B Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, Kumar Prabhash, Konstantinos N Syrigos, Conrad R Lewanski

Lancet· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.
Siow Ming Lee, Conrad R Lewanski, Nicholas Counsell, Christian Ottensmeier, Andrew Bates

J Natl Cancer Inst· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.
Siow Ming Lee, Iftekhar Khan, Sunil Upadhyay, Conrad Lewanski, Stephen Falk

Lancet Oncol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A rare complication of finger sepsis secondary to blood glucose monitoring.
Margaret G Keane, Jacob Haboubi, Conrad Lewanski

BMJ Case Rep· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superior vena cava stent migration into the pulmonary artery causing fatal pulmonary infarction.
Girija Anand, Conrad R Lewanski, Steven A Cowman, James E Jackson

Cardiovasc Intervent Radiol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis